Cassava Announces Closure of U.S. Department of Justice Investigation

Core Viewpoint - Cassava Sciences, Inc. has resolved investigations by the U.S. Department of Justice and the U.S. Securities and Exchange Commission regarding allegations of research misconduct and negligence-based disclosure charges, allowing the company to refocus on its development of treatments for CNS disorders [1][2][3] Group 1: Investigations and Resolutions - The U.S. Department of Justice closed its inquiry into Cassava Sciences regarding allegations of research misconduct, with the related indictment dismissed with prejudice on October 23, 2025 [1] - The company reached a settlement with the U.S. Securities and Exchange Commission in September 2024, paying a monetary penalty without admitting or denying the allegations [2] - Both investigations have concluded, allowing the company to move forward without these legal concerns [2] Group 2: Company Focus and Future Plans - Cassava Sciences remains committed to maintaining stakeholder trust and will continue to focus on developing novel treatments for TSC-related epilepsy [3] - The company is engaged in developing investigational treatments, including simufilam, for CNS disorders [4]